Investors & Media Press Releases

Press Releases

Summary Toggle

05.28.2020

Summary Toggle Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

Summary ToggleNEW YORK and BASEL, Switzerland , May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani , Pharm.D., SVP of Commercial Strategy and Operations, will
Read More

PDF Version
Read More
Summary Toggle

05.07.2020

Summary Toggle Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Summary ToggleNEW YORK and BASEL, Switzerland , May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced upcoming presentations regarding its investigational gene therapy programs,
Read More

PDF Version
Read More
Summary Toggle

04.24.2020

Summary Toggle Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

Summary ToggleCompany’s balance sheet is now free of debt NEW YORK and BASEL, Switzerland , April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million
Read More

PDF Version
Read More
Summary Toggle

04.15.2020

Summary Toggle Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

Summary TogglePartnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland , April 15, 2020 (GLOBE NEWSWIRE)
Read More

PDF Version
Read More
Summary Toggle

04.08.2020

Summary Toggle Axovant Provides Business and Operations Update During the COVID-19 Pandemic

Summary ToggleCompleted dosing of all patients in second cohort of AXO-Lenti-PD dose escalation study At present, Company remains on track to achieve key 2020 milestones NEW YORK and BASEL, Switzerland , April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

03.31.2020

Summary Toggle Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Summary ToggleNEW YORK and BASEL, Switzerland , March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that management will participate in the virtual Guggenheim Healthcare Talks:
Read More

PDF Version
Read More
Summary Toggle

02.24.2020

Summary Toggle Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to
Read More

PDF Version
Read More
Summary Toggle

02.19.2020

Summary Toggle Axovant Gene Therapies Announces Pricing of $65 Million Public Offering

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share.
Read More

PDF Version
Read More
Summary Toggle

02.19.2020

Summary Toggle Axovant Gene Therapies Announces Commencement of Public Offering

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares.
Read More

PDF Version
Read More
Summary Toggle

02.10.2020

Summary Toggle Axovant Announces Financial Results for Third Fiscal Quarter and Nine Months Ended December 31, 2019

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial results for its third fiscal quarter ended December 31, 2019 .
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search